TB-500 and Tissue Repair: What the Research Shows

The wound-healing data, quantified

TB-500 tissue repair claims rest, at their strongest, on a single well-characterized animal study. In a rat full-thickness wound model, full-length thymosin beta-4 — topical or intraperitoneal — increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, raised wound contraction by at least 11% by day seven, and increased collagen deposition and angiogenesis ^[3]. In the same work, as little as 10 pg of thymosin beta-4 stimulated keratinocyte migration two- to three-fold ^[3].

The magnitudes are worth stating plainly because they are large and they are measured. A 42–61% acceleration of re-epithelialization is a substantial effect for a wound-repair agent. The honest framing is equally plain: this is the parent protein, in rats, by topical and intraperitoneal routes — not the TB-500 heptapeptide, and not a human result. The picogram-level keratinocyte activity is in-vitro.

This is the anchor of the latest thymosin beta-4 research on repair, and it is the reason wound healing dominates the TB-500 narrative. It is also the reason the identity caveat matters most here: the headline numbers belong to the 4963 Da protein.

Burn, venous-ulcer, and corneal repair

Beyond the rat wound model, the repair literature widens — and stays, for the most part, on the parent protein. Thymosin beta-4 improved dermal burn-wound healing via downregulation of the receptor for advanced glycation end-products in a db/db mouse model ^[8]. A European prospective, randomized study reported wound-healing benefit with thymosin beta-4 in venous (pressure/stasis) ulcers — among the earliest human wound-healing observations for the protein ^[7].

The ophthalmic line is the one with the most human-trial development: clinical-grade topical thymosin beta-4 (RGN-259) has been studied in dry-eye and corneal-healing trials. Extending that work, a 2025 study reported that an engineered tandem thymosin peptide promoted corneal wound healing — a next-generation construct built for greater repair potency ^[16].

Across these tissues the pattern holds: the protein, or an engineered derivative of it, accelerates repair in animal models and a few topical human studies. The isolated TB-500 fragment is not the molecule in these studies. Where you read 'thymosin beta-4' here, read the parent protein.

Why the repair signal does not equal a human result

Two facts keep the repair story honest. First, there are zero completed controlled clinical trials of the TB-500 heptapeptide for any indication ^[6]; the human record is the parent protein's Phase 1 IV safety study and topical ophthalmic trials, neither of which tested the fragment for tissue repair ^[6]. Second, the preclinical record is not uniformly positive: in dystrophin-deficient mdx mice, chronic thymosin beta-4 increased regenerating fibers but did not improve muscle strength, cardiac function, or fibrosis, and systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study.

The dose response is also non-monotonic. In the rat embolic-stroke study, 2 and 12 mg/kg improved outcomes but 18 mg/kg did not ^[4] — higher is not necessarily better, which directly undercuts community 'loading' rationales. The 2026 Sports Medicine review states the boundary for this audience: favorable animal-model repair outcomes, scarce rigorous human safety data, potential for serious harm, and operation largely outside regulatory oversight ^[11].

So the repair signal is real, reproducible in places, and large in the best wound study — and it is preclinical, mostly on a different molecule than the one sold as TB-500, with no completed fragment trial behind it. The findings and the gap are both on the record.

Inline questions on tissue repair

These appear inline here and in full on the FAQ index.